LICENSE, TRANSFER, AND DEVELOPMENT AGREEMENT BY AND AMONG SERENITY PHARMACEUTICALS LLC AND ALLERGAN SALES, LLC, ALLERGAN USA, INC., AND ALLERGAN, INC. MARCH 31, 2010, and Development Agreement • April 2nd, 2010 • Allergan Inc • Pharmaceutical preparations • New York
THIS LICENSE, TRANSFER, AND DEVELOPMENT AGREEMENT (the “Agreement”) is made and entered into as of March 31, 2010 (the “Effective Date”) by and among SERENITY PHARMACEUTICALS LLC, a Delaware limited liability company with a principal place of business at 105 Hawk Court, Milford, PA 18337 (“Serenity”), and ALLERGAN SALES, LLC, a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan Sales”), ALLERGAN USA, INC., a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan USA”), and ALLERGAN, INC., a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan, Inc.” and, collectively with Allergan Sales and Allergan USA, “Allergan”). Serenity and Allergan are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
